NEUROCRINE BIOSCIENCES INC - 8-K Filing
Neurocrine Biosciences reports Q3 2026 revenue of $1.1 billion, a 41% year-over-year increase driven by INGREZZA and CRENESSITY sales. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $NBIX
Read the full article at SEC EDGAR
Part of the story SHENANDOAH TELECOMMUNICATIONS CO/VA/ - 8-K Filing (57 articles)